Stayin’ Alive: GSK Sees Options For Brand Advair In A Post-Generic World

Payers might be open to keeping the Advair brand on formulary even if a generic becomes available, because GSK has a portfolio of respiratory drugs to leverage in negotiations, CEO Andrew Witty said during the company’s third quarter conference call.